Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients

Citation
Ec. Johnstone et al., Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients, CANC CHEMOT, 46(6), 2000, pp. 433-441
Citations number
35
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN journal
03445704 → ACNP
Volume
46
Issue
6
Year of publication
2000
Pages
433 - 441
Database
ISI
SICI code
0344-5704(200012)46:6<433:IMADDI>2.0.ZU;2-O
Abstract
Purpose: This study was designed to determine individual variation in the m etabolism of ifosfamide (IF) and any influence this may have on the degree of DNA damage produced in both peripheral blood lymphocytes (PBL) and in tu mour tissue. Methods: The pharmacokinetics and metabolism of IF and also of doxorubicin (DOX) were determined in patients receiving IF/DOX neoadjuvant chemotherapy for the treatment of advanced breast cancer. The DNA-damaging effects of this regimen were measured using the comet assay in PBL and in breast tumour tissue obtained by fine needle aspirate. Parallel in vitro st udies were carried out in order to establish if DNA damage caused by IF met abolites or DOX was predictive of cytotoxicity in breast cancer cell lilies . Results: The median AUG, half-life and clearance of IF were found to be 2 91 muM min, 5.2 h and 66 ml/min per m(2), respectively. A high degree of in terpatient variability (up to sevenfold) was observed in the metabolism of both IF and DOX and also in their metabolites. Treatment-related changes in the amount of DNA damage were observed in both PBL and tumour cells. That in PBL peaked 48 h after the end of IF infusion (median 17% damaged cells a t 48 h compared to 4% damaged before treatment). DNA damage in tumour cells was not elevated above low pretreatment values (median 1.5% damaged cells) until 3 weeks after IF and DOX treatment (median 30% damaged cells), by wh ich time damage in PBL showed almost complete resolution to basal levels. T he DNA damage in PBL determined 24 h after the start of chemotherapy was fo und to be related to the AUC of 4-hydroxyifosfnmide (40HI; P = 0.05). The a mount of damage in either tissue did not significantly correlate with clini cal response or toxicity, but lower amounts of damage were observed in the tumour cells 3 weeks after treatment in those patients that subsequently re lapsed, compared to those that remained disease free. DNA damage (more than 20% damaged cells) was observed after exposure to active IF metabolites at concentrations equal to or greater than the IC50 in MCF-7 and MDA-MB231 ce ll lines. At concentrations of 4OHI similar to those determined in vivo, an equivalent level of DNA damage was observed in PBL and in cell lines and w as associated with significant growth inhibition. DNA damage induced by DOX was not. predictive of cytotoxicity. Conclusion: Systemic DNA damage appea red to be related to levels of the active metabolite, consistent with the r esults of in vitro investigations of DNA damage. Further studies are warran ted to substantiate this observation and to explore the relationship betwee n metabolism, DNA damage and antitumour activity.